Behrends Matthias, Peters Jürgen
Klinik für Anästhesiologie und Intensivmedizin, Universitätsklinikum Essen, Hufelandstrasse 55, 45122 Essen, Germany.
Intensive Care Med. 2003 Oct;29(10):1802-7. doi: 10.1007/s00134-003-1879-8. Epub 2003 Jul 17.
Sepsis-evoked myocardial dysfunction is possibly due to decreased myofilament calcium sensitivity, and a calcium sensitizer may thus specifically improve contractility in sepsis by enhancing myofilament calcium sensitivity. We examined whether the calcium sensitizer levosimendan mitigates myocardial dysfunction and improves contractility in hearts isolated from endotoxin-treated guinea pigs.
Prospective, controlled, randomized animal study in a university research laboratory.
Guinea pig hearts isolated 4 h (n=10) or 18 h (n=8) following E. coli LPS (4 mg/kg i.p.) and hearts from sham-treated controls (n=11 and n=6).
Isolated hearts were perfused at constant aortic pressure [Krebs-Henseleit buffer, heart rate: 300/min, left ventricular (LV) diastolic pressure: 6-8 mmHg], and LV developed pressure (LVd P) and LVd P/d t were continuously assessed. Levosimendan was added to the perfusate in incremental concentrations (0.03, 0.1, 0.3 microM).
Endotoxin resulted in a significant decrease in LVd P by 20+/-6% and 43+/-8%, in +LVd P/d t by 16+/-5% and 44+/-7%, and in -LVd P/d t by 27+/-8% and 47+/-8% after 4 and 18 h, respectively. In septic hearts levosimendan increased LV function concentration-dependently by 32+/-4% (LVd P), 33+/-5% (+LVd P/d t), and 37+/-7% (-LVd P/d t) 4 h and by 31+/-6% (LVd P), 33+/-6% (+LVd P/d t), and 32+/-7% (-LVd P/d t) 18 h after LPS. However, levosimendan increased myocardial function similarly in control hearts.
While the calcium sensitizer levosimendan markedly improved LV contractility in hearts from both endotoxic and sham animals, it failed to specifically abolish endotoxin-evoked myocardial dysfunction. Thus, decreased calcium sensitivity either does not play a major role in endotoxin-evoked cardiomyopathy or the location of its pathomechanism differs from levosimendan's site of action.
脓毒症诱发的心肌功能障碍可能是由于肌丝钙敏感性降低,因此钙增敏剂可能通过增强肌丝钙敏感性来特异性改善脓毒症时的心肌收缩力。我们研究了钙增敏剂左西孟旦是否能减轻内毒素处理的豚鼠离体心脏的心肌功能障碍并改善其收缩力。
在大学研究实验室进行的前瞻性、对照、随机动物研究。
大肠杆菌脂多糖(4mg/kg腹腔注射)处理4小时(n = 10)或18小时(n = 8)后分离的豚鼠心脏,以及假处理对照组的心脏(n = 11和n = 6)。
离体心脏在恒定主动脉压下灌注[克雷布斯-亨塞尔特缓冲液,心率:300次/分钟,左心室(LV)舒张压:6 - 8mmHg],并持续评估左心室舒张末压(LVdP)和LVdP/dt。左西孟旦以递增浓度(0.03、0.1、0.3微摩尔)添加到灌注液中。
内毒素导致4小时和18小时后LVdP分别显著降低20±6%和43±8%,+LVdP/dt分别降低16±5%和44±7%,-LVdP/dt分别降低27±8%和47±8%。在脓毒症心脏中,左西孟旦在脂多糖处理4小时后使LV功能浓度依赖性增加32±4%(LVdP)、33±5%(+LVdP/dt)和37±7%(-LVdP/dt),18小时后增加31±6%(LVdP)、33±6%(+LVdP/dt)和32±7%(-LVdP/dt)。然而,左西孟旦在对照心脏中同样增加了心肌功能。
虽然钙增敏剂左西孟旦显著改善了内毒素处理动物和假处理动物心脏的左心室收缩力,但它未能特异性消除内毒素诱发的心肌功能障碍。因此,钙敏感性降低要么在内毒素诱发的心肌病中不起主要作用,要么其病理机制的位置与左西孟旦的作用部位不同。